|
||||||||||||
 |
||||||||||||
|
||||||||||||
Top Stories
Immunize.org Pages and Handouts
Vaccine Information Statements
Featured Resources
Notable Publications
Upcoming Events
Top Stories
Immunize.org summarizes ACIP’s September 1 meeting recommending bivalent mRNA COVID-19 vaccines for fall booster doses
The Advisory Committee on Immunization Practices (ACIP) met on September 1, 2022, to discuss FDA’s August 31 Emergency Use Authorizations (EUAs) of new bivalent formulations of Pfizer-BioNTech and Moderna mRNA COVID-19 vaccines as a booster dose. The ACIP recommendations represent a fundamental reset of the COVID-19 vaccination schedule for every person age 12 years and older.
ACIP members discussed that, while the FDA-authorized interval of 2 months between the completion of a primary series or the most recent booster is acceptable, longer intervals of 3–6 months may be preferred depending upon individual circumstances. Factors influencing timing include recent recovery from COVID-19 infection, risks related to travel or work, or the patient’s risk of serious complications of COVID-19 infection due to age or health status. Evidence suggests longer intervals produce a stronger immune response, as well as a reduced risk of myocarditis in individuals at increased risk for myocarditis after vaccination (e.g., adolescent and adult males under 40). Individuals recently recovered from COVID-19 may wait up to 90 days after illness before bivalent booster vaccination. ACIP members noted that CDC should carefully outline these issues for healthcare providers in its updated interim clinical considerations guidance. Clinical Considerations All healthcare professionals who administer COVID-19 vaccines should carefully review CDC’s updated Vaccines & Immunizations: Use of COVID-19 Vaccines in the U.S. summarizing interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States for specific guidance on appropriate use of these newly recommended boosters. A few important highlights include:
As immunity conferred by past doses wanes, studies of hospitalization and mortality rates have made the importance of receiving the recommended bivalent boosters clear. A recent publication presented during the ACIP meeting projects that a fall-winter (September 2022 through March 2023) vaccination campaign with expanded eligibility for bivalent boosters and high booster coverage could avert 100,000 to 160,000 deaths and 1 to 1.7 million hospitalizations in the coming months. Related Links
Immunize.org’s 2022–2023 standing orders for administering influenza vaccine to adults and to children and teens now available for healthcare providers
Immunize.org recently posted its updated 2022–2023 Standing Orders for Administering Influenza Vaccine to Children and Teens and Standing Orders for Administering Influenza Vaccine to Adults.
 
Related Links
Immunize.org’s 2022–2023 recipient screening forms for contraindications and precautions to influenza vaccination now available for healthcare providers
Immunize.org's 2022–2023 recipient screening forms, Screening Checklist for Contraindications to Inactivated Injectable Influenza Vaccination and Screening Checklist for Contraindications to Live Attenuated Intranasal Influenza Vaccination, are now available for healthcare providers to print and use. Both forms display new footers that include a QR code on the first page. Scan the QR code to access the current document on your mobile devices.
"National Vaccination Coverage among Adolescents Aged 13–17 Years—National Immunization Survey-Teen, United States, 2021" published in MMWR
CDC published National Vaccination Coverage among Adolescents Aged 13–17 Years—National Immunization Survey-Teen, United States, 2021 on September 2 in MMWR. A portion of the summary appears below. As more adolescents who were due for routine vaccinations during the pandemic age into the NIS-Teen sample, the full impact of the pandemic can be assessed. Providers should review vaccination records to ensure that adolescents are current with all recommended vaccinations. Access the MMWR article in HTML or PDF.
"COVID-19 mRNA Vaccine Safety among Children Aged 6 Months–5 Years—United States, June 18, 2022–August 21, 2022" published in MMWR
CDC published COVID-19 mRNA Vaccine Safety among Children Aged 6 Months–5 Years—United States, June 18, 2022–August 21, 2022 on December 31 on September 2 in MMWR. A portion of the summary appears below. Local and systemic reactions after vaccination with either BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) COVID-19 vaccines were reported for children aged 6 months–4 years and 6 months–5 years, respectively, to v-safe and VAERS safety monitoring systems. Serious adverse events were rarely reported.... Initial vaccine safety data indicate that among young children, local and systemic reactions are expected after COVID-19 vaccination and serious adverse events are rare.
In this week's Immunize.org spotlight, we summarize resources at Immunize.org grouped by age cohorts. Journalists seek out Immunize.org experts to help explain vaccines to the public and policy makers. We help the media understand and communicate the complex work vaccinators do. Here is a selection of our recent citations.
These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.
Immunize.org Pages and Handouts
Immunize.org posts eight printable resources to help you kick off a successful 2022–2023 influenza vaccination season. All now have QR codes for easy access to electronic versions on mobile devices.
In addition to its very popular standing orders templates and screening checklists for contraindications, Immunize.org has posted eight additional influenza vaccination season resources reviewed and updated, as needed, for the 202–2023 season. On each document, you will now find a QR code in the footer that can be scanned to access the document on your mobile devices. In the future, these QR codes will bring you to the most current online version of the document every time.
Other influenza-related resources
Related Links
Back to top
Recap: These updated Immunize.org educational materials and web pages for clinicians were released during July and August IZ Express regularly provides readers with information about Immunize.org’s new and updated educational materials and web pages. All Immunize.org materials are free to distribute.
Vaccine Information Statements
IZ Express regularly provides readers with information about new and updated Vaccine Information Statements (VISs) and their translations.
Featured Resources
Help Immunize.org reach more vaccinators through your social media networks. Follow us and share our posts featuring Ask the Experts questions and our clinical resources on Facebook, Twitter, and Instagram!
Immunize.org launched a new social media program to highlight our educational resources for a new audience of vaccinators. Our social media channels now feature our most popular printable resources and Ask the Experts questions, as well as announcements important to frontline vaccinators. Our Instagram account is new and we need your support to build our following! Like, follow, and share Immunize.org’s social media accounts and encourage colleagues and others interested in vaccination to do likewise:
Each additional follower extends the reach of our work to help healthcare professionals deliver quality vaccination services to people of all ages. Campus COVID-19 Vaccine and Mitigation Initiative offers resources and toolkits to combat misinformation and increase vaccine confidence on college campuses
The Campus COVID-19 Vaccination and Mitigation Initiative (CoVAC), an initiative of the American College Health Association in collaboration with CDC, aims to increase vaccine confidence and combat vaccine misinformation on college campuses. To do this, CoVAC provides students and other campus stakeholders relevant, credible, accurate information on the importance of getting vaccinated, vaccine safety, and where to get vaccinated.  The program offers various resources, including:
Explore the www.Give2MenACWY.org website to increase coverage for the MenACWY booster and other adolescent vaccinations
Immunize.org's www.Give2MenACWY.org website promotes the importance of adolescent vaccination, including the recommended MenACWY vaccine booster dose at age 16. Many teens are behind on vaccines because of the pandemic, so vaccination is more important than ever. The website is divided into five easy-to-access sections:
The site also categorizes materials according to whether they are primarily of interest to providers, to adolescents, or to parents.
Notable Publications
"Parental Intentions and Perceptions toward COVID-19 Vaccination among Children Aged 4 Months to 4 Years—PROTECT Cohort, Four States, July 2021–May 2022" published in MMWR
CDC published Parental Intentions and Perceptions toward COVID-19 Vaccination among Children Aged 4 Months to 4 Years—PROTECT Cohort, Four States, July 2021–May 2022 on September 2 in MMWR. A portion of the summary appears below. In June 2022, COVID-19 vaccines were authorized for use in children aged 6 months–5 years. Intent to vaccinate and vaccination rates in children have been low.... During July 2021–May 2022, in a longitudinal cohort of 393 children aged <5 years in four states, parental intent to vaccinate children against COVID-19 and perception of COVID-19 vaccine safety and effectiveness declined over a 3-month period, but intent to vaccinate and perceptions of vaccine safety returned to baseline after 6 months.... Identifying and addressing barriers to COVID-19 vaccination in children aged <5 years and educating parents about COVID-19 vaccine effectiveness and safety in young children are critical to increasing pediatric COVID-19 vaccination coverage.
"Booster COVID-19 Vaccinations among Persons Aged ≥5 Years and Second Booster COVID-19 Vaccinations among Persons Aged ≥50 Years—United States, August 13, 2021–August 5, 2022" published in MMWR
CDC published Booster COVID-19 Vaccinations among Persons Aged ≥5 Years and Second Booster COVID-19 Vaccinations among Persons Aged ≥50 Years—United States, August 13, 2021–August 5, 2022 on September 2 in MMWR. A portion of the summary appears below. A COVID-19 vaccine booster dose provides enhanced protection against SARS-CoV-2 infection, COVID-19–associated emergency department visits, hospitalization, and death.... Among 214 million eligible persons aged ≥5 years, approximately one half received a booster dose. Among 55 million eligible persons aged ≥50 years, approximately one third received a second booster dose. Booster and second booster dose coverage rates were lower among the youngest age groups; males; non-Hispanic Black or African American, Hispanic or Latino, and multiracial persons; residents of rural counties; and Janssen (Johnson & Johnson) primary series recipients.... Focused interventions to improve vaccine equity and effectiveness of outreach to populations with low booster and second booster dose coverage should be developed and implemented. Access the MMWR article in HTML or PDF.
“Prevalence of Human Papillomavirus Infection among Women Born in the 1990s vs the 1980s and Association with HPV Vaccination in the U.S.” published in JAMA
In the August 19 issue, JAMA published Prevalence of Human Papillomavirus Infection among Women Born in the 1990s vs the 1980s and Association with HPV Vaccination in the U.S. The discussion section appears below. These study findings suggest that HPV vaccination was associated with a reduction in HPV-16/18 infection prevalence among a recent birth cohort of vaccinated and unvaccinated 18- to 26-year-old women. A larger decline in the prevalence of HPV-16/18 infection among 18- to 20-year-old women during the 2015−2016 time period may reflect greater direct and herd protection from broader HPV vaccination coverage. Upcoming Events
Virtual: North Dakota State University offers webinar “COVID-19 and Vaccines: Science vs. Antiscience” on September 26
North Dakota State University's (NDSU) Center for Immunization Research and Education (CIRE) will host a webinar titled COVID-19 and Vaccines: Science vs. Antiscience at 12:00 p.m. (CT) on September 26. The webinar will feature Peter J. Hotez, MD, PhD, discussing COVID-19 vaccine diplomacy and the impact of antivaccine sentiment and activities. On-demand: CDC’s “The Pink Book” chapter webinars on vaccine-preventable diseases and best practices roll out weekly. Polio and Hib chapters now available, with CE.
CDC continues its 19-part pre-recorded webinar series to provide a chapter-by-chapter overview of the 14th edition of Epidemiology and Prevention of Vaccine-Preventable Diseases (also known as "The Pink Book"). For more upcoming events, visit our Calendar of Events.
|
||||||||||||
|
